Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Input metadata references "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Report Date: March 29, 2013
Reporting Period: The filing announces results of operations for the quarter and year ended December 31, 2012.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not contain specific numerical values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Margins
- Debt or Liquidity positions
Conclusion: The filing text does not provide a clear value for any specific financial metric; these figures are contained in the referenced Exhibit 99.1.
Material Changes
The filing text does not describe specific material changes versus the prior comparable period. It only confirms that results for the quarter and year ended December 31, 2012, have been reported.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 will not be treated as "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name (RXi Pharmaceuticals Corporation vs. Phio Pharmaceuticals Corp.) to ensure accurate data retrieval.
- Locate and review Exhibit 99.1 (Press Release dated March 29, 2013) to obtain actual revenue, profit, and cash flow figures.
- Confirm the specific operational results for the quarter and full year ended December 31, 2012, as they are not listed in the 8-K body.
- Check for any forward-looking statements or risk factors included in the attached press release.